All news

Teva gains after guidance lift and Bioepis deal

Alpha Vantage · Simply Wall St · · AI-summarised by FinFlash

Teva shares rose 5.58% over seven days and are up 30.85% year to date, closing at $42.97, after the company reported lower net income but raised 2026 revenue guidance and expanded immunology biosimilars through a Samsung Bioepis deal. Simply Wall St sees TEVA 12% undervalued with a $48.94 fair value, though execution and pipeline risks persist.

Read original source

TEVA company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.